Citigroup Inc Atara Biotherapeutics, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Atara Biotherapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 18,686 shares of ATRA stock, worth $144,069. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,686

Previous 14,010 33.38%

Holding current value

$144,069

Previous $7,000 71.43%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.44 - $1.22 $2,057 - $5,704	4,676 Added 33.38%	18,686 $12,000
Q4 2023 Feb 09, 2024	SELL	$0.23 - $1.74 $100,991 - $764,020	-439,092 Reduced 96.91%	14,010 $7,000
Q3 2023 Nov 09, 2023	SELL	$1.41 - $2.31 $40,386 - $66,165	-28,643 Reduced 5.95%	453,102 $670,000
Q2 2023 Aug 10, 2023	SELL	$1.5 - $3.04 $644,211 - $1.31 Million	-429,474 Reduced 47.13%	481,745 $775,000
Q1 2023 May 11, 2023	SELL	$2.8 - $5.46 $319,757 - $623,526	-114,199 Reduced 11.14%	911,219 $2.64 Million

Q4 2022 Feb 09, 2023	SELL	$2.85 - $5.18 $753,007 - $1.37 Million	-264,213 Reduced 20.49%	1,025,418 $3.36 Million
Q3 2022 Nov 10, 2022	BUY	$2.85 - $8.73 $729,847 - $2.24 Million	256,087 Added 24.78%	1,289,631 $4.88 Million
Q2 2022 Aug 10, 2022	BUY	$4.69 - $9.84 $789,796 - $1.66 Million	168,400 Added 19.46%	1,033,544 $8.05 Million
Q1 2022 May 12, 2022	SELL	$8.44 - $16.89 $1.25 Million - $2.5 Million	-148,135 Reduced 14.62%	865,144 $8.04 Million
Q4 2021 Feb 10, 2022	BUY	$14.7 - $19.89 $10.9 Million - $14.8 Million	742,430 Added 274.11%	1,013,279 $16 Million
Q3 2021 Nov 10, 2021	BUY	$11.99 - $17.9 $3.25 Million - $4.85 Million	270,849 New	270,849 $4.85 Million

Others Institutions Holding ATRA

# of Institutions

Shares Held

85M

Call Options Held

18.4K

Put Options Held

51.3K

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account